Recommended Citation
Zidan A. Evolving Strategies in Lipid Lowering Therapy Post-Coronary CT Angiogram: A Decadal Analysis at Aurora St. Luke’s Medical Center (2012-2022). Presented at Scientific Day; May 21, 2025; Park Ridge, IL.
Abstract
Background/Significance:
Coronary CT angiography (CCTA) has emerged as a transformative tool in cardiovascular imaging, significantly impacting the landscape of lipid lowering therapy. Beyond its diagnostic capabilities, CCTA has become a catalyst for personalized medicine, influencing therapeutic strategies in the management of coronary artery disease, particularly in lipid lowering therapy.
Purpose:
This investigation seeks to contribute to the optimization of lipid lowering strategies based on non-invasive coronary imaging.
Methods:
We conducted a retrospective analysis utilizing electronic health records at our center to investigate the impact of CCTA on lipid lowering therapy trends. The study cohort comprised consecutive patients who underwent CCTA in the outpatient setting. Data on patient demographics and clinical characteristics, including pre-existing conditions and information on the status of lipid lowering therapy both prior to and following CCTA, were collected and examined.
Results:
A total of 5,948 unique patients were included in this study. The mean age was 59 years (± 13 years), 54% of patients were female and 62% had hyperlipidemia at the time of CCTA. Notably, 69.4% (4,129/5,948) were already on lipid lowering therapy before the CCTA. Following CCTA, 19.4% (1,153/5,948) of patients experienced optimization in lipid lowering therapy. Among those initially not on lipid lowering therapy (1,189 patients), 30.5% (554 patients) initiated therapy based on CCTA findings. In contrast, among those already on lipid lowering therapy (4,129 patients), 13.5% (559 patients) underwent an intensification of their regimen.
Conclusion:
This 10-year outpatient study reveals a significant impact of CCTA on lipid lowering therapy. The findings highlight the pivotal role of CCTA in guiding therapeutic decisions, leading to the initiation or intensification of lipid lowering therapy in nearly one-fifth of patients. This underscores the clinical relevance of incorporating CCTA into lipid management strategies, contributing to personalized cardiovascular care, and potentially reducing long-term cardiovascular risk.
Presentation Notes
Presented at Scientific Day; May 21, 2025; Park Ridge, IL.
Full Text of Presentation
wf_yes
Document Type
Oral/Podium Presentation
Evolving Strategies in Lipid Lowering Therapy Post-Coronary CT Angiogram: A Decadal Analysis at Aurora St. Luke’s Medical Center (2012-2022)
Background/Significance:
Coronary CT angiography (CCTA) has emerged as a transformative tool in cardiovascular imaging, significantly impacting the landscape of lipid lowering therapy. Beyond its diagnostic capabilities, CCTA has become a catalyst for personalized medicine, influencing therapeutic strategies in the management of coronary artery disease, particularly in lipid lowering therapy.
Purpose:
This investigation seeks to contribute to the optimization of lipid lowering strategies based on non-invasive coronary imaging.
Methods:
We conducted a retrospective analysis utilizing electronic health records at our center to investigate the impact of CCTA on lipid lowering therapy trends. The study cohort comprised consecutive patients who underwent CCTA in the outpatient setting. Data on patient demographics and clinical characteristics, including pre-existing conditions and information on the status of lipid lowering therapy both prior to and following CCTA, were collected and examined.
Results:
A total of 5,948 unique patients were included in this study. The mean age was 59 years (± 13 years), 54% of patients were female and 62% had hyperlipidemia at the time of CCTA. Notably, 69.4% (4,129/5,948) were already on lipid lowering therapy before the CCTA. Following CCTA, 19.4% (1,153/5,948) of patients experienced optimization in lipid lowering therapy. Among those initially not on lipid lowering therapy (1,189 patients), 30.5% (554 patients) initiated therapy based on CCTA findings. In contrast, among those already on lipid lowering therapy (4,129 patients), 13.5% (559 patients) underwent an intensification of their regimen.
Conclusion:
This 10-year outpatient study reveals a significant impact of CCTA on lipid lowering therapy. The findings highlight the pivotal role of CCTA in guiding therapeutic decisions, leading to the initiation or intensification of lipid lowering therapy in nearly one-fifth of patients. This underscores the clinical relevance of incorporating CCTA into lipid management strategies, contributing to personalized cardiovascular care, and potentially reducing long-term cardiovascular risk.
Affiliations
Aurora St. Luke’s Medical Center